MedTrace Logo

Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients

NCT01694927 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-07-03

No results posted yet for this study

Summary

The aim of this study is to evaluate the use of autologous expanded mesenchymal stem cells intralesional transplantation as a safe and potentially beneficial treatment for patients with spinal cord injury.

Conditions

  • Spinal Cord Injury

Interventions

PROCEDURE

Autologous Mesenchymal Stem Cells

Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation

Sponsors & Collaborators

  • Clínica Las Condes. LIT INNOVA CORFO

    lead OTHER

Principal Investigators

  • Andrés Chahín, MD · Clínica Las Condes, Santiago

  • Rodrigo M Mardones, MD · Clínica Las Condes, Santiago

  • Catalina Larrain, MD · Clínica Las Condes, Santiago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-12-31
Completion
2014-06-30

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01694927 on ClinicalTrials.gov